Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faster Submissions For Orphan Designation Possible As EMA’s Online Portal Goes Live

Executive Summary

The new portal is expected to provide an improved method for applying for and managing EU orphan drug designations.

You may also be interested in...



EMA Reports Progress with EU Clinical Trial & Orphan IT Systems

The European Medicines Agency says progress is being made with new IT systems for clinical trial and orphan designation applications in the EU. 

EMA Portal To Speed Things Up For Parallel Distributors

The European Medicines Agency says that its IRIS portal will reduce the time needed for parallel distributors to prepare and submit notifications.

Mid-June Launch For EMA’s Simplified Online Orphan Designation Filing System

The European Medicines Agency will encourage companies to submit their orphan designation applications through a new portal when it is launched on June 15. Applications through existing processes will be accepted until Sept. 15.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel